Unknown

Dataset Information

0

Serum antibodies to blood group A predict survival on PROSTVAC-VF.

ABSTRACT: PURPOSE:There is evidence that therapeutic cancer vaccines can lengthen survival for some patients with cancer, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. EXPERIMENTAL DESIGN:This retrospective study included 141 subjects from phase II trials of PROSTVAC-VF, a poxvirus-based cancer vaccine currently in phase III clinical trials for advanced prostate cancer. A glycan microarray was used to profile prevaccination antiglycan antibody populations in sera as potential biomarkers for PROSTVAC-VF. The screen for predictive biomarkers identified antiglycan antibodies that consistently stratified subjects into groups with different Kaplan-Meier survival estimates. Because of the potential for overfitting, a permutation test was used to estimate the false discovery rate. RESULTS:Prevaccination antibody levels to blood group A trisaccharide (BG-Atri) were found to have a statistically significant correlation with survival. Long-term survival was approximately doubled in subjects with abundant anti-BG-Atri immunoglobulin M (IgM) relative to subjects with little or no preexisting IgM for BG-Atri. This survival correlation was specific to vaccine treatment, as no correlation was observed in control patients immunized with wild-type poxviruses lacking the key tumor antigen, prostate-specific antigen (PSA). Moreover, anti-BG-Atri IgM levels were not correlated with general measures of disease severity, such as PSA levels, Gleason score, or Halabi predicted survival. CONCLUSION:In addition to reporting a new potentially predictive biomarker for PROSTVAC-VF, this study highlights the use of glycan microarray technology for improving our understanding of vaccine immunology. Clin Cancer Res; 19(5); 1290-9. ©2012 AACR.

SUBMITTER: Campbell CT 

PROVIDER: S-EPMC3594414 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Serum antibodies to blood group A predict survival on PROSTVAC-VF.

Campbell Christopher T CT   Gulley James L JL   Oyelaran Oyindasola O   Hodge James W JW   Schlom Jeffrey J   Gildersleeve Jeffrey C JC  

Clinical cancer research : an official journal of the American Association for Cancer Research 20130129 5

<h4>Purpose</h4>There is evidence that therapeutic cancer vaccines can lengthen survival for some patients with cancer, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy.<h4>Experimental design</h4>This retrospective study included 141 subjects from phase II trials of PROSTVAC-VF, a poxvirus-based cancer vaccine currently in phase III clinical trials for advance  ...[more]

Similar Datasets

Unknown Humoral response to a viral glycan correlates with survival on PROSTVAC-VF.
| S-EPMC4035954 | biostudies-literature
Proteomics Baseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine
2013-04-01 | GSE42184 | GEO
Proteomics Baseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine
2013-04-01 | E-GEOD-42184 | biostudies-arrayexpress
Proteomics Baseline serum anti-glycan IgM antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
2015-08-26 | GSE50237 | GEO
Proteomics Baseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation IgM 1:50]
2013-04-01 | GSE42175 | GEO
Proteomics Baseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training IgM 1:50]
2013-04-01 | GSE42020 | GEO
Proteomics Baseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training IgG 1:50]
2013-04-01 | GSE42019 | GEO
Proteomics Baseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation IgG 1:50]
2013-04-01 | GSE42163 | GEO
Proteomics Post-vaccination serum anti-glycan IgG antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
2015-08-26 | GSE50235 | GEO
Proteomics Baseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation Total Ig 1:50]
2013-04-01 | GSE42176 | GEO